Changes in buprenorphine visits in frontier and remote locations: Effects of the SARS-CoV-2 pandemic.  McFadden LM.  Drug Alcohol Depend Rep. 2023 Jun;7:100155. doi: 10.1016/j.dadr.2023.100155. Epub 2023 Mar 29. PMID: 37065774; PMCID: PM…

Interrupted Time Series Analysis: Patient Characteristics and Rates of Opioid-Use-Disorder-Related Emergency Department Visits in the Los Angeles County Public Hospital System during COVID-19.  Johnson E, Axeen S, Vosooghi A, Lam CN, Bluthenth…

Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.  Kline A, Williams JM, Steinberg ML, Mattern D, Chesin M, Borys S, Chaguturu V.  J Subst Use Addi…

Rapid adaptation during the COVID crisis: Challenges experienced in delivering service to those with Opioid Use Disorders.  Hills HA, Lengnick-Hall R, Johnson KA, Vermeer W, Hendricks Brown C, McGovern M.  Implement Res Pract. 2022 Apr 2…

"As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.  Jaffe K, Blawatt S, Lehal E, Lock K, Easterbrook A, MacDonald S, Harrison S, Lajeunesse J, Byres D, Schechter…

Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies.  Giang K, Charlesworth R, Thulien M, Mulholland A, Barker B, Brar R, Pauly B, Fast D.  Int J Drug…